TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35797024
Drug: Saline nasal
Normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline nasal irrigation (SNI) with placebo (500 mg lactose powder)
Study: 35243022
Drug: Stereotactic Ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic Ablative Radiotherapy (SABR) in combination with ongoing systemic therapy
Study: 35243022
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (switch to the next line of treatment, continue same treatment or observation)
Study: 34159208
Drug: Overall PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall PRP group (intraoperative PRP augmentation)
Study: 35060543
Drug: Lung-conduction exercises
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung-conduction exercises (LCE), medication + LCE, 5 times a week, n = 8
Study: 35060543
Drug: Pulmonary rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary rehabilitation (PR), medication + PR, 5 times a week, n = 8
Study: 35060543
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (SC), only medication, n = 9
Study: 34473334
Drug: Curcuminoids (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (exact dosage and duration not specified)
Study: 34970882
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of vitamin B1 into ST36 and LI4, once every other day, three times a week.
Study: 34970882
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate tablets (5 mg) taken orally 30 min before each of the three meals.
Study: 35811251
Drug: Oral Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Acetazolamide 20 mg/kg/day in 3-4 divided doses for 7 days plus Corrected body (prone) position (CP+A)
Study: 33515093
Drug: Oily fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oily fish (300 g/week)
Study: 615007039
Drug: rhSA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhSA treatment
Study: 33704459
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg quinine hydrochloride (QHCl) administered intragastrically (IG)
Study: 33704459
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg quinine hydrochloride (QHCl) administered intraduodenally (ID)
Study: 33704459
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no quinine) administered intragastrically (IG)
Study: 33704459
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no quinine) administered intraduodenally (ID)
Study: 33704459
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg quinine hydrochloride (QHCl)
Study: 32357579
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D tablets (1600 IU/day)
Study: 32357579
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D tablets (1600 IU/day) in patients without immunoglobulin replacement
Study: 33634677
Drug: 2 daily
Normalized name: INV-PAXLOVID 150MGX4/100MGX2 DAILY PKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 daily sessions per muscle group (2S)
Study: 33634677
Drug: 1 daily
Normalized name: PAXLOVID 150MGX2/100MGX1 DAILY PKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 daily session per muscle group (1S)
Study: 32805434
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of intervention
Study: 35339908
Drug: Family-oriented dignity
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-oriented dignity therapy
Study: 34371972
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DHA-rich n-3 PUFA supplementation and RT
Study: 35433468
Drug: dSAPB combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: dSAPB combined with 30 ml of 0.375% ropivacaine (Group R)
Study: 35433468
Drug: dSAPB combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: dSAPB combined with 30 ml of 0.375% ropivacaine plus dexmedetomidine (1 μg/kg) (Group RD)
Study: 36231235
Drug: True SAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: True SAS intervention (daily self-administered acupressure on specific acupoints for seven weeks)
Study: 32861500
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of epinephrine 0.1 μg kg-1 min-1
Study: 32861500
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of phenylephrine 1 μg kg-1 min-1
Study: 32861500
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of epinephrine
Study: 32861500
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of phenylephrine
Study: 87088248
Drug: Alcohol-Focused Spouse
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol-Focused Spouse Involvement plus Behavioral Marital Therapy (ABMT)
Study: 35996106
Drug: Robot-assisted virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted virtual reality mirror therapy (RAVRMT)
Study: 35996106
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality mirror therapy (VRMT)
Study: 34808745
Drug: DRG‐PRF treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRG‐PRF treatment assisted by 3D‐printed navigation template
Study: 34808745
Drug: DRG‐PRF treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRG‐PRF treatment guided by conventional CT
Study: 38601720
Drug: Pulsed Electric
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed Electric Field (PEF) treatment
Study: 35587714
Drug: Spironolactone treatment
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone treatment in Phenotype 1
Study: 34540184
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine with 1 ?g/kg DEX (PRD group)
Study: 34540184
Drug: Routine general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine general anesthesia (G group)
Study: 33852780
Drug: Psilocybin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (25 mg, two doses 3 weeks apart plus 6 weeks of daily placebo)
Study: 33852780
Drug: Escitalopram (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (1 mg, two doses 3 weeks apart plus 6 weeks of daily oral escitalopram)
Study: 33485646
Drug: 3.75 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 µg H7N9 IIV adjuvanted with MF59
Study: 33485646
Drug: 7.5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 µg H7N9 IIV adjuvanted with MF59
Study: 33485646
Drug: 15 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 µg H7N9 IIV adjuvanted with MF59
Study: 33485646
Drug: 3-dose series
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-dose series on days 1, 28 and 168
Study: 33485646
Drug: 3-dose series
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-dose series on days 1, 57 and 168
Study: 33485646
Drug: Recent prior
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent prior receipt of seasonal influenza vaccine
Study: 35952426
Drug: Test agent
Normalized name: Adenosine 3mg/1mL Solution for injection [Cardiac Stress Test Agent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test agent nasal spray, administered 3 times daily over a 45 day course
Study: 35936366
Drug: Carvedilol combined
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol combined with conventional antihypertensive therapy
Study: 33492568
Drug: Abemaciclib 150
Normalized name: abemaciclib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 150 mg every 12 h on a 28-day cycle
Study: 33492568
Drug: Abemaciclib 200
Normalized name: abemaciclib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 200 mg every 12 h on a 28-day cycle
Study: 33586058
Drug: Patient-managed titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-managed titration of insulin glargine 300 U/mL (Gla-300)
Study: 33586058
Drug: Physician-managed titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-managed titration of insulin glargine 300 U/mL (Gla-300)
Study: 36336245
Drug: Ivermectin Mass
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin Mass Drug Administration (MDA)
Study: 34114623
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg dosing
Study: 34641897
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist pretreatment for 3 days before stimulation
Study: 34641897
Drug: Conventional GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional GnRH antagonist protocol (without pretreatment)
Study: 34641897
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist pretreatment
Study: 34448875
Drug: 700 mg
Normalized name: cystine 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg phosphorus (NaH2PO4)
Study: 34152936
Drug: Indoor daylight
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoor daylight photodynamic therapy (idl-PDT)
Study: 37838653
Drug: internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-based cognitive behavioral therapy (iCBT)
Study: 35304401
Drug: Demanding amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Demanding amoxicillin
Study: 35304401
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not demanding any medicine)
Study: 33819217
Drug: Exer-gaming for
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exer-gaming for 30 minutes twice a week for 8 weeks
Study: 33819217
Drug: Balance training
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance training exercises twice a week for 8 weeks
Study: 36425335
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with transfer factor capsules
Study: 36425335
Drug: Cryotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy with transfer factor capsules
Study: 34400956
Drug: Oral betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral betamethasone therapy (3 mg, once a week) with placebo
Study: 34400956
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (15 mg, once a week) with placebo
Study: 34400956
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (methotrexate 15 mg, once a week and betamethasone 3 mg, once a week)
Study: 36226802
Drug: Intralesional normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional normal saline solution (Control)
Study: 33724296
Drug: Chemoradiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy with concurrent capecitabine (arm B)
Study: 33603097
Drug: Organic carbon
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Organic carbon exposure (increase of 0.51 μg/m3)
Study: 33603097
Drug: Sodium exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium exposure (increase of 0.06 μg/m3)
Study: 34304913
Drug: FDC IBU/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC IBU/APAP 250 mg/500 mg
Study: 34304913
Drug: APAP 500
Normalized name: Mapap 500mg Caplet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APAP 500 mg
Study: 34304913
Drug: FDC IBU/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC IBU/APAP 250 mg/500 mg, IBU 250 mg, APAP 500 mg
Study: 34304913
Drug: FDC IBU/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC IBU/APAP 250 mg/500 mg, placebo
Study: 32423576
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (1 g + 0.9% normal saline 100 mL)
Study: 32423576
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TXA (2 g + 0.9% normal saline 50 mL)
Study: 34262263
Drug: AMPH ER
Normalized name: AMPH-b
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMPH ER TAB (amphetamine extended-release tablet)
Study: 32957900
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise program (REP, 50‐60% of 1RM, for 40‐50 min) combined with metformin
Study: 32957900
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise program (AEP, 50‐70% maxHR, for 40‐50 min) combined with metformin
Study: 32957900
Drug: Metformin without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin without exercise intervention (Met group)
Study: 35420554
Drug: Combination prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination prevention (CP) including intensive testing, linkage campaigns, expanded ART, and voluntary male medical circumcision referrals
Study: 34620454
Drug: Fast Track
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast Track and Standard Treatment Trial (FASTT)
Study: 34620454
Drug: Trying to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trying to conceive without treatment
Study: 33684737
Drug: n−3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n−3 PUFA (2.2 g/day)
Study: 33571959
Drug: Concurrent endurance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent endurance and strength training (n = 14)
Study: 35029748
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy with phycocyanin
Study: 35029748
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy with toluidine blue O
Study: 35871490
Drug: Intralesional bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional bleomycin (1.5 mg/ml)
Study: 35871490
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone (20 mg/ml)
Study: 33840229
Drug: Benralizumab single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab single dose (30 mg)
Study: 33840229
Drug: Benralizumab q4w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab q4w (30 mg every 4 weeks for a total of three doses)
Study: 33840229
Drug: Benralizumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab (both dosing regimens)
Study: 32275368
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with conventional symptomatic and supportive treatments
Study: 32275368
Drug: Symptomatic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic and supportive treatments (control group)
Study: 35114800
Drug: Neoadjuvant intraperitoneal‐systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant intraperitoneal‐systemic chemotherapy
Study: 35114800
Drug: Paclitaxel +
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel + S‐1 (PS) chemotherapy
Study: 33026517
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ICG injection at 8 hours prior to surgery
Study: 33026517
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ICG injection at 10 hours prior to surgery
Study: 33026517
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ICG injection at 12 hours prior to surgery
Study: 33026517
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ICG injection at 14 hours prior to surgery
Study: 36364825
Drug: Live Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live Lactobacillus paracasei (L-PS23, 2 × 10^10 CFU/day)
Study: 35235198
Drug: Intervention Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Group (IG): 40–45 kcal and 1.5 g protein/kg/day; diet plus polymeric formula
Study: 34202877
Drug: Glucosamine hydrochloride
Normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine hydrochloride (3000 mg GlucosaGreen®)
Study: 36424008
Drug: Tofogliflozin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofogliflozin (20 mg/d)
Study: 36424008
Drug: Anagliptin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagliptin (200 mg/d)
Study: 36067615
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg twice daily) plus bevacizumab (15 mg/kg every 3 weeks) for up to 24 months and 15 months respectively
Study: 36067615
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus bevacizumab (15 mg/kg every 3 weeks) for up to 15 months
Study: 36067615
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg twice daily) plus bevacizumab (15 mg/kg every 3 weeks)
Study: 36067615
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus bevacizumab (15 mg/kg every 3 weeks)
Study: 33789008
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg every 2 weeks for 16 weeks, followed by 480 mg every 4 weeks)
Study: 34969541
Drug: Cholvax (Incepta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholvax (Incepta Vaccine Ltd)
Study: 33026142
Drug: Short acting
Normalized name: Prolixin (short acting injection) 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short acting BP medication added in the evening
Study: 33026142
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication change (control)
Study: 35255880
Drug: Barberry (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barberry (10 g/day dried barberry)
Study: 32339447
Drug: hIL-7-hyFc (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: hIL-7-hyFc (20, 60 μg/kg s.c. or 60 μg/kg i.m.)
Study: 35867702
Drug: PegIFN alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN alfa‐2a (180 μg/week) for 48 weeks
Study: 33561041
Drug: Forest Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forest Therapy (FT) intervention
Study: 35849276
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate at a dose of 250 mg/kg (at 8 mg/kg/min) once daily for 3 days along with therapeutic hypothermia
Study: 35849276
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate and therapeutic hypothermia
Study: 34670201
Drug: Continuous theta
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous theta burst stimulation (cTBS) administered over one of three stimulation targets in randomized order.
Study: 35979351
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments (historical controls)
Study: 33326179
Drug: Aflibercept (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (2.0 mg/50 µl)
Study: 33326179
Drug: Ranibizumab (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.5 mg/50 µl)
Study: 32663660
Drug: Prolonged anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged anticoagulation (intravenous unfractionated heparin, subcutaneous enoxaparin, or intravenous bivalirudin) for at least 48 hours after pPCI
Study: 35551533
Drug: Vaginal hormone-free
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal hormone-free moisturising cream
Study: 35551533
Drug: Vaginal estriol
Normalized name: estriol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estriol (0.1%) cream
Study: 32897015
Drug: Nefradoz (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefradoz (150 mg, 2 times a day for 28-30 days)
Study: 32897015
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (general recommendations and standard diet therapy for 28-30 days)
Study: 34371810
Drug: Curcumin (HydroCurcTM;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (HydroCurcTM; 500 mg) with low dose iron (18 mg)
Study: 34371810
Drug: Curcumin (HydroCurcTM;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (HydroCurcTM; 500 mg) with high dose iron (65 mg)
Study: 34371810
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose iron (18 mg) with curcumin placebo
Study: 34371810
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose iron (65 mg) with curcumin placebo